Key result
Monthly bladder instillations of doxorubicin hydrochloride controlled tumor recurrence, achieving a median remission of 10 months in 8 of 13 patients with recurring stage A transitional cell carcinoma.
Why the study?
Does monthly bladder instillation of doxorubicin hydrochloride prevent tumor recurrence in patients with recurring superficial transitional cell carcinoma of the bladder?
Population
15 patients
Design
Case_series
Follow-up
up to 21 months
Authors
Loading...
May support intravesical doxorubicin in refractory cases; hypothesis-generating from Level 5 data and should not change practice.
Observational (n=15)
Does monthly bladder instillation of doxorubicin hydrochloride prevent tumor recurrence in patients with recurring superficial transitional cell carcinoma of the bladder?
Monthly topical instillation of doxorubicin hydrochloride may provide effective control of tumor recurrence in patients with superficial transitional cell carcinoma of the bladder.
Banks et al. (1977) conducted an observational in Recurring stage A transitional cell carcinoma of the bladder (n=15). Topical instillation of doxorubicin hydrochloride was evaluated on Tumor recurrence and remission. Monthly bladder instillations of doxorubicin hydrochloride controlled tumor recurrence, achieving a median remission of 10 months in 8 of 13 patients with recurring stage A transitional cell carcinoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: